LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Pipeline Review, H1 2018

  • ID: 4583875
  • Drug Pipelines
  • 32 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • BioTherapeutics Inc
  • Landos Biopharma Inc
  • MORE
LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Pipeline Review, H1 2018

Summary:

LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) pipeline Target constitutes close to 8 molecules. The latest report LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Pipeline Review, H1 2018, outlays comprehensive information on the LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - LanC-like protein 2 is a protein encoded by the LANCL2 gene. It is important for abscisic acid (ABA) binding on the cell membrane and activation of the ABA signaling pathway in granulocytes. The molecules developed by companies in Preclinical stages are 8 respectively. Report covers products from therapy areas Metabolic Disorders, Infectious Disease, Gastrointestinal and Immunology which include indications Type 2 Diabetes, Crohn's Disease (Regional Enteritis), Influenza A Virus, H1N1 Subtype Infections, Influenza A Virus, H3N2 Subtype Infections, Rheumatoid Arthritis, Type 1 Diabetes (Juvenile Diabetes), Ulcerative Colitis and Unspecified Influenza Virus Infections.

Furthermore, this report also reviews key players involved in LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2)
  • The report reviews LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) targeted therapeutics
Reasons to buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • BioTherapeutics Inc
  • Landos Biopharma Inc
  • MORE
Introduction

Report Coverage

LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Overview

LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Companies Involved in Therapeutics Development

BioTherapeutics Inc

Landos Biopharma Inc

LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Drug Profiles

BT-11 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BT-110 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BT-12 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BT-13 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BT-15 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BTABA-5a - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NSC-61610 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize LANCL2 for Type II Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Dormant Products

LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Product Development Milestones

Featured News & Press Releases

Jun 05, 2018 : Landos Biopharma Announces Human Translational Results for Mechanisms of BT-11 in IBD at Digestive Disease Week 2018

May 01, 2018 : Mechanistic and Human Translational Results for BT-11 in Models of IBD

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by BioTherapeutics Inc, H1 2018

Pipeline by Landos Biopharma Inc, H1 2018

Dormant Projects, H1 2018

List of Figures

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • BioTherapeutics Inc
  • Landos Biopharma Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll